FASN and tuberculosis: The mycolic acid synthesis inhibitors currently used in TB treatment, isoniazid and ethionamide/prothionamide, target the mycobacterial fatty acid synthase II (FAS-II) component enoyl-acyl carrier protein reductase InhA.